一线吡咯替尼治疗晚期HER2突变非小细胞肺癌:一项以患者为中心的2期试验
该研究在2期适应性伞式试验中设置符合标准队列(CF)和扩展入组标准下的同情用药队列(CU),并平行开展前瞻性真实世界研究(RWS),共纳入48例初治晚期HER2突变非小细胞肺癌患者,分别接受泛HER受体酪氨酸激酶抑制剂吡咯替尼(CF和CU队列)或医生选择的治疗方案(RWS队列)。CF队列(n=28)客观缓解率为35.7%,疾病控制率89.3%,中位无进展生存期7.3个月,中位总生存期14.3个月,3级或4级治疗相关不良事件发生于3例患者(10.7%);CU队列(n=12)客观缓解率16.7%,疾病控制率83.4%,中位无进展生存期4.7个月,中位总生存期14.2个月;RWS队列(n=8)对医生选择的治疗方案无缓解,中位无进展生存期和总生存期分别为3.0个月和12.2个月。
要点
- CF队列(n=28)吡咯替尼治疗后客观缓解率达35.7%,达到主要终点。
- CF队列3级或4级治疗相关不良事件发生于3例患者(10.7%),毒性可接受。
- RWS队列(n=8)对医生选择的治疗方案无缓解。
核心结论
- 在初治晚期HER2突变非小细胞肺癌患者中,吡咯替尼在2期试验CF队列达到主要终点,客观缓解率为35.7%,毒性可接受。
研究设计与样本
- 2期适应性伞式试验,包含符合标准队列(CF)和扩展入组标准下的同情用药队列(CU),并平行开展前瞻性真实世界研究(RWS)。
- 共纳入48例初治晚期HER2突变非小细胞肺癌患者,CF队列n=28,CU队列n=12,RWS队列n=8。
- CF和CU队列接受泛HER受体酪氨酸激酶抑制剂吡咯替尼治疗,RWS队列接受医生选择的治疗方案。
主要发现
- CF队列(n=28)吡咯替尼治疗后客观缓解率为35.7%,达到主要终点。
- CF队列疾病控制率89.3%,中位无进展生存期7.3个月,中位总生存期14.3个月。
- CF队列3级或4级治疗相关不良事件发生于3例患者(10.7%),毒性可接受。
- CU队列(n=12)吡咯替尼治疗后客观缓解率16.7%,疾病控制率83.4%,中位无进展生存期4.7个月,中位总生存期14.2个月。
- RWS队列(n=8)对医生选择的治疗方案无缓解,中位无进展生存期3.0个月,中位总生存期12.2个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC) with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in parallel, a phase 2 adaptive umbrella trial consisting of a criteria-fulfilled (CF) cohort and a compassionate use (CU) cohort under expanded eligibility criteria, and a prospective real-world study (RWS). Here, we present efficacy and safety data from 48 patients with treatment-naive, advanced HER2-mutant NSCLC treated with the pan-HER receptor tyrosine kinase inhibitor pyrotinib (CF and CU cohorts) or physician's therapy of choice (RWS cohort). In the phase 2 trial CF cohort (n = 28), the primary endpoint was reached with an objective response rate of 35.7% after pyrotinib treatment. Secondary endpoints included disease control rate (89.3%), median progression-free survival (PFS) (7.3 months), median overall survival (OS) (14.3 months) and toxicity, which was acceptable, with grade 3 or 4 treatment-related adverse events occurring in three patients (10.7%). The phase 2 trial CU cohort (n = 12) showed an objective response rate of 16.7%, disease control rate of 83.4%, median PFS of 4.7 months and median OS of 14.2 months after pyrotinib treatment. The RWS cohort (n = 8) had no responses to physician's therapy of choice, while median PFS and OS were 3.0 and 12.2 months, respectively. Phase 2 umbrella trial, clinicaltrials.gov identifier: NCT03574402 . RWS, clinicaltrials.gov identifier: NCT03605602 .
引用
- Liu SM, Tu HY, Wei XW, et al. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat Med. 2023. PMID: 37488286. doi:10.1038/s41591-023-02461-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。